Question · asked by 1 review
Metformin vs glibenclamide ‐ neonatal outcomes: Death or serious morbidity composite
- Population
- Infants of women diagnosed with gestational diabetes
- Intervention
- Metformin
- Comparison
- glibenclamide ‐ neonatal outcomes
- Outcome
- Death or serious morbidity composite
Metformin may leads to lower death or serious morbidity composite compared with glibenclamide ‐ neonatal outcomes (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Metformin vs glibenclamide ‐ neonatal outcomes Death or serious morbidity composite · Infants of women diagnosed with gestational diabetes Metformin may leads to lower death or serious morbidity composite compared with glibenclamide ‐ neonatal outcomes (low certainty). Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane Headline outcomes only | RR 0.54 [0.31, 0.94] | 1 study · 159 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.